Iovance Biotherapeutics Company Insiders
| IOVA Stock | USD 10.01 0.25 2.44% |
Iovance Biotherapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Iovance Biotherapeutics suggests that vertually all insiders are extremely bullish. Iovance Biotherapeutics employs about 557 people. The company is managed by 10 executives with a total tenure of roughly 1300 years, averaging almost 130.0 years of service per executive, having 55.7 employees per reported executive.
Iovance Biotherapeutics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-02-20 | Merrill A Mcpeak | Acquired 250000 @ 9.15 | View | ||
| 2023-09-18 | Merrill A Mcpeak | Acquired 10000 @ 5.56 | View | ||
| 2023-09-15 | Wayne P Rothbaum | Acquired 5000000 @ 5.3 | View |
Monitoring Iovance Biotherapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Iovance |
Iovance Biotherapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Iovance Biotherapeutics' future performance. Based on our forecasts, it is anticipated that Iovance will maintain a workforce of about 560 employees by June 2024.Iovance Biotherapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3448) % which means that it has lost $0.3448 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6677) %, meaning that it created substantial loss on money invested by shareholders. Iovance Biotherapeutics' management efficiency ratios could be used to measure how well Iovance Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of May 26, 2024, Return On Tangible Assets is expected to decline to -0.85. In addition to that, Return On Capital Employed is expected to decline to -0.72. At present, Iovance Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 496.1 M, whereas Total Current Assets are forecasted to decline to about 218.7 M.The current year's Common Stock Shares Outstanding is expected to grow to about 246.9 M, whereas Net Loss is projected to grow to (338.5 M).
Iovance Biotherapeutics Workforce Comparison
Iovance Biotherapeutics is currently regarded as number one stock in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 1,214. Iovance Biotherapeutics totals roughly 557 in number of employees claiming about 46% of equities under Health Care industry.
Iovance Biotherapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iovance Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iovance Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Iovance Biotherapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 0.5 | 3 | 6 | 26,458 | 38,163 |
| 2024-03-01 | 2.0 | 24 | 12 | 6,905,591 | 134,279 |
| 2023-12-01 | 0.5 | 3 | 6 | 26,461 | 38,102 |
| 2023-09-01 | 0.8333 | 5 | 6 | 5,036,460 | 38,101 |
| 2023-06-01 | 1.6667 | 10 | 6 | 426,000 | 38,099 |
| 2023-03-01 | 1.0833 | 13 | 12 | 1,224,156 | 241,130 |
| 2022-06-01 | 6.6667 | 20 | 3 | 1,511,709 | 25,501 |
| 2020-06-01 | 0.8333 | 5 | 6 | 210,000 | 181,782 |
| 2020-03-01 | 1.0 | 3 | 3 | 725,000 | 4,185 |
| 2019-09-01 | 0.3333 | 1 | 3 | 160,000 | 4,252 |
| 2019-06-01 | 1.6667 | 5 | 3 | 225,000 | 3,963 |
| 2019-03-01 | 1.0 | 3 | 3 | 700,000 | 4,422 |
| 2018-12-01 | 1.3333 | 4 | 3 | 1,243,053 | 3,963 |
| 2018-09-01 | 1.3333 | 4 | 3 | 175,000 | 3,963 |
| 2018-03-01 | 0.4 | 2 | 5 | 550,000 | 29,408 |
| 2017-12-01 | 0.2 | 1 | 5 | 37,400 | 218,581 |
| 2017-09-01 | 0.6667 | 2 | 3 | 400,000 | 5,981 |
| 2017-06-01 | 2.5 | 5 | 2 | 210,000 | 195,169 |
| 2016-09-01 | 1.3333 | 8 | 6 | 280,000 | 199,200 |
| 2015-06-01 | 2.5 | 5 | 2 | 340,000 | 2,830,682 |
| 2015-03-01 | 0.5 | 2 | 4 | 90,000 | 113,988 |
| 2014-12-01 | 8.0 | 8 | 1 | 319,073 | 100,000 |
| 2014-09-01 | 0.3333 | 1 | 3 | 125,000 | 400,000 |
| 2013-09-01 | 1.5 | 3 | 2 | 40,059,645 | 60,750,000 |
| 2013-06-01 | 0.4 | 4 | 10 | 976,846,104 | 50,008 |
| 2011-09-01 | 1.5 | 3 | 2 | 2,010,000 | 1,600,000 |
Iovance Biotherapeutics Notable Stakeholders
An Iovance Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Iovance Biotherapeutics often face trade-offs trying to please all of them. Iovance Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Iovance Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Esq JD | President, CEO | Profile | |
| Igor Bilinsky | Chief Officer | Profile | |
| Friedrich MD | Chief Officer | Profile | |
| Howard MBA | Chief Officer | Profile | |
| JeanMarc MBA | Chief Officer | Profile | |
| Sara Pellegrino | Vice Relations | Profile | |
| Madan Jagasia | Ex Affairs | Profile | |
| Tracy Winton | Senior Resources | Profile | |
| Brian MBA | Senior Technology | Profile | |
| James MBA | Executive Commercial | Profile |
About Iovance Biotherapeutics Management Performance
The success or failure of an entity such as Iovance Biotherapeutics often depends on how effective the management is. Iovance Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Iovance management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Iovance management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.81) | (0.85) | |
| Return On Capital Employed | (0.69) | (0.72) | |
| Return On Assets | (0.57) | (0.60) | |
| Return On Equity | (0.76) | (0.80) |
The data published in Iovance Biotherapeutics' official financial statements usually reflect Iovance Biotherapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Iovance Biotherapeutics. For example, before you start analyzing numbers published by Iovance accountants, it's critical to develop an understanding of what Iovance Biotherapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Iovance Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Iovance Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Iovance Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Iovance Biotherapeutics. Please utilize our Beneish M Score to check the likelihood of Iovance Biotherapeutics' management manipulating its earnings.
Iovance Biotherapeutics Workforce Analysis
Traditionally, organizations such as Iovance Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Iovance Biotherapeutics within its industry.Iovance Biotherapeutics Manpower Efficiency
Return on Iovance Biotherapeutics Manpower
| Revenue Per Employee | 2.1K | |
| Revenue Per Executive | 118.9K | |
| Net Loss Per Employee | 797.2K | |
| Net Loss Per Executive | 44.4M | |
| Working Capital Per Employee | 354.7K | |
| Working Capital Per Executive | 19.8M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Iovance Stock analysis
When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Iovance Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.81) | Revenue Per Share 0.008 | Return On Assets (0.34) | Return On Equity (0.67) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.